We are still in the early stages after the approval of bispecific antibodies, so there have been a few subgroups analyzed based on risk. However, it looks like the combination of bispecifics talquetamab and teclistimab could be beneficial for one high-risk subgroup: patients with extramedullary disease.

Researchers looked specifically at the potential of teclistimab and talquetamab combination to treat myeloma patients with extramedullary disease. These patients experience “tumors” that can grow out of the bone marrow.

After treatment, there was a high response rate: at all dose levels, patients responded at a rate of 71.4%, with 21.4% of those patients achieving a complete response or better. This is exciting data, and we look forward to more subanalysis of how high-risk myeloma patients respond to bispecific antibody therapies.

Other therapies, like cevostamab, targeting FcRH5, are supposed to be beneficial for high-risk multiple myeloma patients, but more clinical trial data is needed.

Learn more about high-risk multiple myeloma: Diagnosed With High-Risk Myeloma, What Now? (2024)